Selecting initial therapy in CLL.

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Targeted therapy has surpassed chemoimmunotherapy for chronic lymphocytic leukemia (CLL).
• Most CLL patients benefit from continuous Bruton's tyrosine kinase (BTK) inhibitors or fixed-duration venetoclax-obinutuzumab.
• Treatment selection is individualized based on patient, disease, and drug factors.

Purpose of the Study:

• To review the current landscape of first-line targeted therapy in CLL.
• To highlight factors influencing treatment selection for CLL patients.
• To discuss emerging combination strategies in CLL treatment.

Main Methods:

• Review of current clinical guidelines and treatment paradigms for CLL.
• Analysis of factors influencing first-line therapy choice in CLL.
• Summary of ongoing clinical trials investigating novel CLL therapies.

Main Results:

• Targeted therapies like BTK inhibitors and venetoclax-obinutuzumab are superior to chemoimmunotherapy for most CLL patients.
• Patient preference, comorbidities, and TP53 status guide treatment decisions.
• Combination therapies targeting BTK and BCL-2 show high rates of undetectable minimal residual disease (52%-89%).

Conclusions:

• Targeted therapy is the standard of care for first-line CLL treatment.
• Personalized treatment selection is crucial for optimizing outcomes in CLL.
• Simultaneous inhibition of BTK and BCL-2 is a promising strategy for achieving deep responses in CLL.